ArticleFrontiers in oncology2024

Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience.

Gunnar Wichmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.